
Opinion|Videos|April 10, 2025
The Future of Pulmonary Fibrosis Management: Precision Medicine, Biomarkers and AI
Author(s)Eric Cannon, PharmD, FAMCP
Eric Cannon, PharmD, FAMCP, discusses how precision medicine advancements and biomarker development can enable targeted idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) therapies by identifying patient subgroups most likely to benefit from specific interventions. Artificial intelligence (AI) integration offers potential for earlier diagnosis, improved prognostication and personalized treatment optimization through data pattern recognition.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How can advancements in precision medicine and biomarker development improve treatment strategies for pulmonary fibrosis?
- How do you envision AI impacting management strategies of patients with IPF and PPF?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Langlara, third interchangeable biosimilar to Lantus, approved by FDA
2
FDA approves first treatment for chronic hepatitis D virus
3
Cancer patients taking GLP-1s less likely to develop advanced disease | ASCO 2026
4
Family healthcare costs reach $37,824, analysis finds
5






















